BARRON'S See What Others Don't.

2006 CCR Advertsising Rates

(Effective January 2, 2006)

Communicate everything you want, when you want… in Barron's **Current Corporate Reports** — the advertising section of late-breaking corporate news.

Advertise in Barron's Current Corporate Reports and you reach America's sophisticated institutional and individual investors, financial professionals and corporate managers within the proper environment for the dissemination of corporate news. Your release is an advertisement that appears in news format. It's printed in its entirety while it's still news, too. Corporate news received as late as Thursday afternoon will appear in Barron's on Saturday.

Non-Contract Rates

Per Quarter Inch	$134
Per Inch	$536
Minimum size: 2 inches	$1,072

Special Second-Run Discount: CCR advertisers may run their advertisement a second time at a 50% discount if no changes are made to the advertisement and if it appears in the next week's issue of Barron's.

Advertisers holding a national ROP contract are eligible for the same volume and frequency levels in Current Corporate Reports. (However, Current Corporate Report advertising does not count toward fulfillment of a national ROP contract). Advertisements that appear under the CCR Health, Talking Business and Annual Reports Roundup banners are applicable toward fulfilling a CCR contract.

Frequency Rates

Within One Year	Rate Per Column Inch	Discount
2 issues	$509	5.0%
4 issues	$482	10.0
6 issues	$472	12.0
8 issues	$456	15.0
13 issues	$429	20.0
20 issues	$402	25.0

Mechanical Requirements

Heading (company name): Pub-set 10 pt./11 pt. Franklin Gothic Heavy all caps. 29 characters per line including spaces. Sub-Head: Pub-set 9.5 pt./11 pt. Franklin Gothic Demi-Bold italics, initial caps. 34 characters per line including spaces. (7 lines of sub-head text equals one inch.)

Body copy: Pub-set 8.5 pt/9.5 pt. Franklin Gothic Book upper and lower case. 38 characters per line including spaces (eight lines equals one inch). No logos or illustrations.

Talking Business

Talking Business is a special, bannered advertising section that allows an advertiser's message to stand out. Photographs, charts, graphics and logos can be used to promote the company's message. Advertising is limited to a half-page minimum.

Full Page	$24,563
Half Page	$12,927

Multi-Section Discount: Advertise in CCR, CCR Health, and Annual Reports Roundup in one calendar year and get a 15% discount on the full package.

Closing and Cancellation Date

For CCR:
Thursday, 4:00 p.m. (ET) preceding date of issue.

For Talking Business:
Wednesday, 4:00 p.m. (ET) preceding date of issue.

Where to Send Insertion Orders, Instructions and Materials

Barron's Current Corporate Reports
Craig Schoenhaus, Manager of Direct Sales
1155 Avenue of the Americas
New York, New York 10036-6710
Tel: 212-597-5982, Fax: 212-597-5931

October 11, 2004 BARRON'S • Technology Week T5

SPECIAL ADVERTISING SECTION

Current Corporate Reports

N • NEW YORK Q • NASDAQ V • VANCOUVER T • TORONTO U • OTC BULLETIN BD A • AMERICAN P • PACIFIC C • CANADIAN VENTURE EXCHANGE M • MIDWEST X • CHICAGO STOCK EXCHANGE

COMPANY NEWS OF INTEREST TO INVESTORS

To place your advertisement call, 1,800,227,0245

AQUACELL TECHNOLOGIES, INC. A

Signs Agreement With Rite Aid

RANCHO CUCAMONGA, CA, October 07–AquaCell (AMEX: AQA) announced that it has signed a Water Cooler Placement Agreement with Rite Aid Corp (NYSE: RAD) pursuant to which AquaCell will be installing its free patented Aquacell 1000 Bottled Water Cooler System in the pharmacy areas of Rite Aid stores.

Rite Aid, the third largest drug chain in America with more than 3000 stores, conducted an extensive test on the performance of Aquacell's coolers in their corporate office as well as in several stores. Under an initial term of five years, Rite Aid has agreed that AquaCell's water coolers will be installed on a national basis at no cost to Rite Aid, and that AquaCell may sell the advertising space on the bottle band. The initial rollout, expected to be completed by the end of December, will entail replacing water fountains in approximately half of the stores. Aquacell has been manufacturing coolers in anticipation of this agreement and is in position to use current inventory to supply the water coolers for these initial locations without any delay.

James Witham, AquaCell's CEO said, "We are excited that the third largest drug store chain in the country has signed up for our program. The signing of this agreement is significant to the Company because the placement of the coolers represents the key first step in our revised business model to generate revenues through the sale of advertising on the bottle band of our water coolers. We are excited by the potential advertising revenue stream that could be generated from the placements in Rite Aid stores over the term of the agreement."

Mr. Witham continued, "Replacing outdated water fountains in their stores with our free bottled water coolers complements Rite Aid's desire to provide excellent customer service and satisfaction to their shoppers. Coupling this with the advertising on the bottle band, we believe Rite Aid will enjoy a two pronged benefit of satisfying customers and increasing impulse sales."

By having the free Aquacell Bottled Water Cooler Systems installed in the store, whereby the store is providing a refreshing cup of water, customers can easily take pill-form medication right away. As the customer takes a drink, the advertisement on the cooler gets face-to-face impact with the consumer.

Mr. Witham concluded, "This is only the beginning. As retailers continue to seek means to enhance customer service we expect to sign other contracts in the near future for our free cooler offer to other drug chains, supermarkets and mass merchandisers."

About AquaCell

AquaCell, based in Rancho Cucamonga, CA, through its Aquacell Media, Inc. operating subsidiary, installs its patented self-filling Aquacell 1000 Bottled Water Cooler Systems free of charge into various locations, including retail establishments. AquaCell Media retains ownership of the coolers, and revenue is generated through the sale of targeted advertising on the band of the cooler's permanently attached five-gallon bottle of products and/or services pertinent to the location, similar to the concept of billboard advertising. The Company also manufactures products for water filtration and purification through its two operating subsidiaries, Global Water-Aquacell, Inc. and Water Science Technologies, Inc. Its products address various water treatment applications for industrial, commercial, institutional and residential applications. These applications range from providing purified drinking water - through its point-of-use patented self-filling water cooler and production of water bottling plant equipment- to processing water for ultra-pure purposes, such as micro-chip and pharmaceutical manufacturing.

Contact: Karen Laustsen
Phone (909) 987-0456
www.aquacell.com

DIASYS CORPORATION A

Reports 57% Increase In First Quarter Year Over Year Revenues

WATERBURY, CT, Oct. 6–DiaSys Corporation (AMEX:DYX) a global healthcare products company, reported sales results for the first quarter ended September 30, 2004. Revenue was $568,456 in the first quarter of 2004, an increase of 57% over revenue of $361,388 in the first quarter of 2003.

"We have made excellent progress on all our stated goals during the first quarter and will continue to see accelerating sales growth" said Morris Silverman, Chairman. "We are generating increasing sales as a result of our new sales team. We remain very committed to reaching our long term goals for the Company."

Contact: Gregory Witchel, CEO
Phone (203) 755-5083, www.diasys.com

ICEWEB, INC. U

IceWEB Awarded Blanket Purchase Agreement By US Patent And Trademark Office Contract Limit Is $25,000,000 Over 3 years

HERNDON, VA, Sep. 24–IceWEB announced it has been awarded a Blanket Purchase Agreement (BPA) by the United States Patent & Trademark Office (USPTO) to serve as a source for the acquisition of Information Technology Equipment, Software and Services. As a result of this award, the USPTO recently placed its first task order for information technology equipment that exceeds $120,000.

This USPTO BPA Order number DOC45PAPT0400057, expires on June 30th, 2006, with three additional one year options to renew. The authorized limit for purchasing through this BPA is $25 Million with a call not to exceed $5,000,000 on any one task order.

This BPA, awarded to only 16 firms nationwide, provides the USPTO and all other agencies it supports with the ability to purchase information technology products and services through the web. IceWEB was selected for this contract award based on stringent performance guidelines outlined by the USPTO, and the depth and quality of its product catalogue. An additional requirement for selection was IceWEB's ability for USPTO contracting personnel to purchase mission critical technology products online. This system was designed specifically with customers like the USPTO in mind, keeping the purchasing process simple, manageable and hassle-free.

Contact: Michael N. Cachine,COO
Phone (703) 964-8000 x126
info@iceweb.com

IMMTECH INTERNATIONAL, INC. A

Adds New Strategic Position; Appoints Carol Olson, MD, Ph.D., Vice President And Chief Medical Officer

VERNON HILLS, IL, Oct. 8–Immtech International, Inc. (Amex: IMM) announced that Carol Olson, M.D., Ph.D. has accepted the newly-created position of Vice President and Chief Medical Officer. Dr. Olson will be responsible for the management of the clinical trial programs and medical affairs of the Company, including the development of integrated clinical plans and management of medical related issues with worldwide regulators.

Prior to joining Immtech, Dr. Olson worked at Abbott Laboratories, Pharmaceutical Division for eleven years in various capacities, most recently as Global Project Head and Global Medical Director for Anti-Infective Development. In this function, she had line management responsibility for strategic planning, execution of clinical development plans, manufacturing and commercialization, product safety, scientific communications and regulatory affairs for outpatient respiratory antibiotics, including Clarithromycin and Cefdinir. As part of her responsibilities at Abbott, Dr. Olson managed the filing of Investigative New Drug (IND) applications and New Drug Applications (NDA) with the United States Food and Drug Administration (FDA).

Prior to this position Dr. Olson was Global Franchise Medical Director responsible for the Anti-Infective Franchise Program at Abbott from 2000 -- 2002. In 2001, she participated on a team responsible for Medical Affairs Acquisition & Integration Management for the Knoll/BASF Pharma Acquisitions. During Dr. Olson's initial years at Abbott (1994 - 2000), she held a number of Medical Director Positions for different product groups in the Pharmaceutical Division.

Dr. Olson received both her Medical Doctor degree and Ph.D., Biochemistry, from the University of Chicago. She received a Master of Science degree from North Dakota State University and attended Concordia College, where she earned a B.A. degree. Additionally, Dr. Olson was a Medical Fellow Specialist -- Division of Infectious Diseases, Department of Medicine at the University of Minnesota and Medical Resident, Department of Medicine at the University of Chicago. While at Abbott she earned a number of awards including the Chairman's Award, Abbott Laboratories (1994).

Stephen Thompson, President and CEO said, "We are excited to have her join our management team as we achieve the Company s milestones. Dr. Olson's talent, credentials and experience will enable her to contribute significantly to the Company's successes as Immtech advances its first drug candidate, DB289, towards commercialization."

About Immtech International

Immtech International, Inc. is a pharmaceutical company advancing the development and commercialization of oral drugs to treat infectious diseases and neoplastic (cancer) and metabolic (diabetes) disorders. We are developing treatments for fungal infections, malaria, tuberculosis, cancer, diabetes, Pneumocystis carinii pneumonia ("PCP") and tropical diseases, including African sleeping sickness (trypanosomiasis) and leishmaniasis. We have a worldwide, exclusive license to commercialize a dicationic pharmaceutical platform from which a pipeline of products may be developed to target large, global markets.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K/A for the most recently ended fiscal year.

Contact: F.C. Thompson
Phone (877) 898-8038
news@immtech-international.com
www.immtech-international.com

MEDICURE INC. A

Discovers Breakthrough Drug For Prevention Of Blood Clots – Enters Research Agreement With Loyola University Opinion Leader, Dr. Jawed Fareed To Advance Development Of Drug

WINNIPEG, MANITOBA, Oct. 6–Medicure Inc. (AMEX:MCU; TSX:MPH), a cardiovascular drug discovery and development company, is pleased to announce that preliminary results have shown significant potential for its newest drug, MC-45308, in preventing blood clots. The compound has shown a unique property that demonstrates simultaneous anti-platelet and anti-coagulant effects, which will make MC-45308 a major player in the management strategy of cardiovascular diseases such as Myocardial Infarction (MI), stroke, Pulmonary Emboli (PE) and Peripheral Arterial Disease (PAD). A drug of this type currently is non-existent within the antithrombotic marketplace.

Medicure sees this as a major breakthrough and significant future advantage to clinicians who are prescribing their patients combinations of anti-platelets and anti-coagulants to treat their cardiovascular disorders, stated Medicure President and CEO, Dr. Albert D. Friesen.

The combined U.S. market for antiplatelets and anticoagulants is projected to grow rapidly from an estimated USD$3 billion in 2000 to USD$6.7 billion in 2008.

To advance the development of MC-45308, a novel and composition of matter patented drug from Medicure's antithrombotic library, the Company has entered into a research agreement with Dr. Jawed Fareed, Professor, Departments of Pathology and Pharmacology, Loyola University Stritch School of Medicine, Maywood, Ill.

"This has the potential to be a major discovery in the field of antithrombotic therapy," stated Dr. Fareed. "Our preliminary biochemical results suggest potential for MC-45308, which has a unique property that demonstrates a dual anti-platelet and anti-coagulant effect."

Contact: Derek Reimer, Chief Financial Officer, Phone (888) 435-2220
Fax: (204) 488-9823
info@medicureinc.com
www.medicureinc.com

PETROL OIL & GAS INC. U

Commences CBM Drilling Program Company To Hold Annual Shareholder's Meeting On October 27th

LAS VEGAS, NV, Oct. 7–Petrol Oil and Gas Inc. (OTCBB: POIG) announces that it has commenced activities, employing the proceeds from its recently completed $6.6 million private placement to begin a 25-well drilling program. The initial target for the program will be the Coal Creek Project in Coffey County, Kansas. The company expects to report interim results from the drilling program as they become available.

The program will target the coal seams in southeastern Kansas and could support up to 1,700 producing gas wells. The shallow depths associated with the multiple coal seams results in low drilling and production costs, and a higher probability of production. The flat terrain of Eastern Kansas, which allows for ease of access for drilling rigs and associated production equipment, should enable the Company to progress quickly with the drilling program.

The Company also announced that it will hold its Annual Shareholder's Meeting on Wednesday, October 27 at 10:00 am at the Alexis Park Resort, located at 375 E. Harmon Avenue in Las Vegas, Nevada. At the time, Company executives are expected to further update investors on the activities from the drilling program.

Contact: Investor Information
Phone (702) 454-7318
www.petroloilandgas.com, or
CEOcast, Inc. for Petrol Oil and Gas
Ed Lewis, Phone (212) 732-4300 x225

© 2006 Dow Jones & Company, Inc. All Rights Reserved.

Issued November 2, 2005

DOWJONES